ICON Public Limited (ICLR)
NASDAQ: ICLR
· Real-Time Price · USD
163.79
1.26 (0.78%)
At close: Sep 26, 2025, 3:59 PM
162.32
-0.90%
After-hours: Sep 26, 2025, 04:42 PM EDT
ICON Public Revenue Breakdown
| Period Ending | Dec 31, 2012 | Sep 30, 2012 | Dec 31, 2011 |
|---|---|---|---|
| Central Laboratory Revenue | 63.49M | 23.98M | 18.67M |
| Central Laboratory Revenue Growth | +164.78% | +28.44% | n/a |
| Clinical Research Revenue | 766.01M | 261.52M | 223.95M |
| Clinical Research Revenue Growth | +192.90% | +16.78% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Jun 30, 2014 | Mar 29, 2014 | Dec 31, 2013 | Dec 31, 2012 | Sep 30, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ireland Revenue | 1.27B | 593.41M | 511.83M | 589.37M | 526.87M | 500.97M | 367.36M | 336.03M | 358.03M | 363.73M | 308.12M | n/a | 250.23M | 279.74M | 314.97M | n/a | 320.46M | 310.48M | 298.48M | 300.26M | 270.71M | 260.12M | 235.11M | 220.58M | 107.82M | 95.89M | 116.78M | 97.3M | 95.65M | 100.83M | 97.07M | 113.06M | 105.41M | 114.09M | 188.1M | 98.13M | 86.4M | 83.27M | 258.07M | 80.47M |
| Ireland Revenue Growth | +114.33% | +15.94% | -13.16% | +11.86% | +5.17% | +36.37% | +9.32% | -6.14% | -1.57% | +18.05% | n/a | -100.00% | -10.55% | -11.18% | n/a | -100.00% | +3.22% | +4.02% | -0.59% | +10.92% | +4.07% | +10.64% | +6.59% | +104.58% | +12.44% | -17.89% | +20.03% | +1.72% | -5.14% | +3.88% | -14.14% | +7.25% | -7.61% | -39.35% | +91.69% | +13.58% | +3.76% | -67.73% | +220.72% | n/a |
| Rest Of Europe Revenue | 786.75M | 373.81M | 414.22M | 336.36M | 397.54M | 428.39M | 456.06M | 465.47M | 471.11M | 118.58M | 120.35M | 124.43M | 100.64M | 89.39M | 102.43M | 106.2M | 98.08M | 94.19M | 90.44M | 96.86M | 91.29M | 96.69M | 95.04M | 169.11M | 89.54M | 78.46M | 81.68M | 76.43M | 79.44M | 75.64M | 88.78M | 79.08M | 78.54M | 84.09M | n/a | n/a | n/a | n/a | n/a | n/a |
| Rest Of Europe Revenue Growth | +110.47% | -9.76% | +23.15% | -15.39% | -7.20% | -6.07% | -2.02% | -1.20% | +297.30% | -1.47% | -3.28% | +23.65% | +12.58% | -12.73% | -3.55% | +8.28% | +4.13% | +4.14% | -6.62% | +6.10% | -5.58% | +1.74% | -43.80% | +88.87% | +14.12% | -3.94% | +6.87% | -3.79% | +5.02% | -14.80% | +12.27% | +0.68% | -6.60% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue | 1.59B | 848.02M | 844.4M | 806.76M | 903.2M | 894.02M | 970.63M | 981.38M | 934.01M | 313.11M | 352.5M | 225.08M | 285.55M | 189.47M | 225.47M | 227.75M | 223.9M | 222.31M | 218.54M | 220.83M | 227.28M | 221.2M | 225.67M | 392.52M | 192.95M | 206.08M | 182.09M | 204.26M | 193.38M | 184.09M | 175.43M | 161.14M | 164.3M | 150.06M | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +87.66% | +0.43% | +4.67% | -10.68% | +1.03% | -7.89% | -1.10% | +5.07% | +198.30% | -11.17% | +56.61% | -21.18% | +50.71% | -15.97% | -1.00% | +1.72% | +0.71% | +1.73% | -1.04% | -2.84% | +2.75% | -1.98% | -42.51% | +103.43% | -6.37% | +13.17% | -10.86% | +5.63% | +5.04% | +4.93% | +8.87% | -1.92% | +9.49% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 205.01M | 198.38M | 151.44M | 205.09M | 194.46M | 177.35M | 195.56M | 185.19M | 187.81M | 200.01M | 226.75M | 166.79M | 189.95M | 195.26M | 202.72M | 206.71M | 109.88M | 98.53M | 87.88M | 83.12M | 83.5M | 87.2M | 86.18M | 85.45M | 83.2M | 81.91M | 83.12M | 80.82M | 80.94M | 80.92M | 82.09M | 79.43M | 80.83M | 81.39M | 83.53M | 81.23M | 80.17M | 80.79M | 83.48M | 82.44M | 81.32M | 79.56M |
| Selling, General, and Administrative Revenue Growth | +3.34% | +30.99% | -26.16% | +5.47% | +9.65% | -9.31% | +5.60% | -1.39% | -6.10% | -11.80% | +35.95% | -12.20% | -2.72% | -3.68% | -1.93% | +88.12% | +11.52% | +12.13% | +5.73% | -0.46% | -4.24% | +1.17% | +0.86% | +2.70% | +1.58% | -1.46% | +2.85% | -0.14% | +0.03% | -1.43% | +3.34% | -1.73% | -0.68% | -2.57% | +2.83% | +1.33% | -0.77% | -3.22% | +1.26% | +1.37% | +2.22% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |